Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
- Conditions
- Wet AMD
- Registration Number
- NCT01310686
- Lead Sponsor
- West Coast Retina Medical Group, Inc.
- Brief Summary
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Ability to provide written informed consent for participation in this study
- Subjects diagnoses of neovascular AMD who are on a monthly anti-VEGF regimen (have had >10 or more ranibizumab and/or bevacizumab injections within the last year) and who still have intra-retinal or subretinal fluid as confirmed by the Investigator
Exclusion Criteria
- Subjects with a Pigment Epithelial Detachment Exclusively
- Subjects with Serous Pigment Epithelial Detachments
- Subjects with history of the following:
idiopathic polypoidal choroidal vasculopathy
- pathologic degenerative myopia
- central serous chorioretinopathy
- familial drusen
- adult onset foveal pattern dystrophy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment This is a one time only blood draw.
- Secondary Outcome Measures
Name Time Method To evaluate demographic and clinical characteristics in patients treated with anti-VEGF therapy who fail to respond completely. This is a one time only blood draw and assessment of clinical characteristics.
Trial Locations
- Locations (1)
West Coast Retina Medical Group, Inc.
🇺🇸San Francisco, California, United States